Tianda Pharmaceuticals Annual Results 2022
HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.
- HONG KONG, June 30, 2022 - (ACN Newswire) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022.
- Innovation and R&D made steady progress with R&D expenses increasing 34.7% year on year (YOY) to HK$15.9 million.
- With cash and cash equivalents of approximately HK$334.0 million as of 31 March 2022, the Group has sufficient financial resources to support its business development.
- The new R&D and production base located in Jinwan, Zhuhai
The Pharmaceuticals and medical technologies business revenue reached HK$396.1 million, an increase of 10.7% YOY.